88 related articles for article (PubMed ID: 16034482)
21. S 26948: a new specific peroxisome proliferator activated receptor gamma modulator with potent antidiabetes and antiatherogenic effects.
Carmona MC; Louche K; Lefebvre B; Pilon A; Hennuyer N; Audinot-Bouchez V; Fievet C; Torpier G; Formstecher P; Renard P; Lefebvre P; Dacquet C; Staels B; Casteilla L; Pénicaud L;
Diabetes; 2007 Nov; 56(11):2797-808. PubMed ID: 17704298
[TBL] [Abstract][Full Text] [Related]
22. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
[TBL] [Abstract][Full Text] [Related]
23. Nuclear receptors, transcription factors linking lipid metabolism and immunity: the case of peroxisome proliferator-activated receptor gamma.
Varga T; Nagy L
Eur J Clin Invest; 2008 Oct; 38(10):695-707. PubMed ID: 18837794
[TBL] [Abstract][Full Text] [Related]
24. Induction of CXCR2 receptor by peroxisome proliferator-activated receptor gamma in human macrophages.
Rigamonti E; Fontaine C; Lefebvre B; Duhem C; Lefebvre P; Marx N; Staels B; Chinetti-Gbaguidi G
Arterioscler Thromb Vasc Biol; 2008 May; 28(5):932-9. PubMed ID: 18292390
[TBL] [Abstract][Full Text] [Related]
25. The many faces of PPARgamma: anti-inflammatory by any means?
Szanto A; Nagy L
Immunobiology; 2008; 213(9-10):789-803. PubMed ID: 18926294
[TBL] [Abstract][Full Text] [Related]
26. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
Hsu MC; Huang CC; Chang HC; Hu TH; Hung WC
Clin Cancer Res; 2008 Jul; 14(13):4045-52. PubMed ID: 18593980
[TBL] [Abstract][Full Text] [Related]
28. Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium.
Achanzar WE; Moyer CF; Marthaler LT; Gullo R; Chen SJ; French MH; Watson LM; Rhodes JW; Kozlosky JC; White MR; Foster WR; Burgun JJ; Car BD; Cosma GN; Dominick MA
Toxicol Appl Pharmacol; 2007 Sep; 223(3):246-56. PubMed ID: 17663016
[TBL] [Abstract][Full Text] [Related]
29. Peroxisome proliferator-activated receptor alpha, delta, gamma1 and gamma2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands.
Jakobsen MA; Petersen RK; Kristiansen K; Lange M; Lillevang ST
Scand J Immunol; 2006 May; 63(5):330-7. PubMed ID: 16640656
[TBL] [Abstract][Full Text] [Related]
30. Peroxisome proliferator-activated receptor gamma ligands stimulate myeloid differentiation and lipogenensis in human leukemia NB4 cells.
Yasugi E; Horiuchi A; Uemura I; Okuma E; Nakatsu M; Saeki K; Kamisaka Y; Kagechika H; Yasuda K; Yuo A
Dev Growth Differ; 2006 Apr; 48(3):177-88. PubMed ID: 16573735
[TBL] [Abstract][Full Text] [Related]
31. Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components.
Martin H
Mutat Res; 2009 Oct; 669(1-2):1-7. PubMed ID: 19563816
[TBL] [Abstract][Full Text] [Related]
32. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents.
Kaundal RK; Sharma SS
Drug News Perspect; 2010 May; 23(4):241-56. PubMed ID: 20520853
[TBL] [Abstract][Full Text] [Related]
33. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
Seimandi M; Lemaire G; Pillon A; Perrin A; Carlavan I; Voegel JJ; Vignon F; Nicolas JC; Balaguer P
Anal Biochem; 2005 Sep; 344(1):8-15. PubMed ID: 16038868
[TBL] [Abstract][Full Text] [Related]
34. Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator.
Thieme TM; Steri R; Proschak E; Paulke A; Schneider G; Schubert-Zsilavecz M
Bioorg Med Chem Lett; 2010 Apr; 20(8):2469-73. PubMed ID: 20307981
[TBL] [Abstract][Full Text] [Related]
35. [Anti-atherosclerotic effects by PPARgamma and its ligands through the activation of reverse cholesterol transport system].
Wakino S; Itoh H
Nihon Rinsho; 2010 Feb; 68(2):217-23. PubMed ID: 20158087
[TBL] [Abstract][Full Text] [Related]
36. Evidence that peroxisome proliferator-activated receptor γ suppresses squamous carcinogenesis through anti-inflammatory signaling and regulation of the immune response.
Ren L; Konger RL
Mol Carcinog; 2019 Sep; 58(9):1589-1601. PubMed ID: 31111568
[TBL] [Abstract][Full Text] [Related]
37. Peroxisome proliferator-activated receptor-γ and the endothelium: implications in cardiovascular disease.
Magri CJ; Gatt N; Xuereb RG; Fava S
Expert Rev Cardiovasc Ther; 2011 Oct; 9(10):1279-94. PubMed ID: 21985541
[TBL] [Abstract][Full Text] [Related]
38. [PPARgamma as a new therapeutic target in inflammatory diseases].
Naito Y; Yoshikawa T
Nihon Rinsho; 2010 Feb; 68(2):341-9. PubMed ID: 20158107
[TBL] [Abstract][Full Text] [Related]
39. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis.
Giaginis C; Giagini A; Theocharis S
Pharmacol Res; 2009 Sep; 60(3):160-9. PubMed ID: 19646655
[TBL] [Abstract][Full Text] [Related]
40. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms.
Straus DS; Glass CK
Trends Immunol; 2007 Dec; 28(12):551-8. PubMed ID: 17981503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
